Sign In
Buy TEVA
$34.43
-0.0300 (-0.0871%)
At Close: Aug 04, 2026
Stock Market Plunge: 2 Value Stocks to Buy and 1 to Avoid Like the Plague
09:06am, Thursday, 12'th May 2022 The Motley Fool
With the broader market tumbling, value stocks are bound to come into focus.
Stock Market Plunge: 2 Value Stocks to Buy and 1 to Avoid Like the Plague
05:06am, Thursday, 12'th May 2022
With the broader market tumbling, value stocks are bound to come into focus.
Teva's Q1 Results: Is the Stock About to Crash?
08:35pm, Thursday, 05'th May 2022 The Motley Fool
The company met analyst expectations for revenue and profitability, yet that's not necessarily a good thing.
Teva's Q1 Results: Is the Stock About to Crash?
04:35pm, Thursday, 05'th May 2022
The company met analyst expectations for revenue and profitability, yet that's not necessarily a good thing.
TEVA Matches Q1 Earnings Estimates, Lowers 2022 Sales View
03:07pm, Wednesday, 04'th May 2022 Zacks Investment Research
TEVA reports in-line Q1 earnings but misses estimates for sales. It lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact.
Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2022
02:17pm, Wednesday, 04'th May 2022 Benzinga
Upgrades
Craig-Hallum upgraded the previous rating for Pros Holdings Inc (NYSE:PRO) from Hold to Buy. Pros Holdings earned $0.21 in the first quarter, compared to $0.22 in the year-ago quarter. At the
TEVA Matches Q1 Earnings Estimates, Lowers 2022 Sales View
12:47pm, Wednesday, 04'th May 2022
TEVA reports in-line Q1 earnings but misses estimates for sales. It lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact.
Teva Pharmaceutical Industries (TEVA) Q1 2022 Earnings Call Transcript
03:00pm, Tuesday, 03'rd May 2022 The Motley Fool
TEVA earnings call for the period ending March 31, 2022.
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
01:01pm, Tuesday, 03'rd May 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours.
Stocks In Focus
Acadia Announces FDA AdComm For Pimavanserin In Alzheimer's-Related Psychosis
The FDA's Psychopharmaco
Teva Pharmaceutical Industries Limited (TEVA) CEO Kåre Schultz on Q1 2022 Results - Earnings Call Transcript
12:22pm, Tuesday, 03'rd May 2022
Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Q1 2022 Results Conference Call May 3, 2022 8:00 AM ET Company Participants Ran Meir - Head, IR Kåre Schultz - CEO Eli Kalif - CFO Sven Dethlefs -
Teva Posts Mixed Q1 Earnings, Cuts FY22 Sales Guidance Citing Copaxone Competition, Yet Shares Rise
10:39am, Tuesday, 03'rd May 2022
Teva Pharmaceutical Industries Ltd's (NYSE: TEVA) Q1 sales reached $3.66 billion, shrinking 8% Y/Y, missing the consensus of $3.75 billion. The decrease is mainly due to lower revenues from generi
Teva Pharm Q1 profit down, cuts 2022 revenue outlook
07:33am, Tuesday, 03'rd May 2022
Israel-based Teva Pharmaceutical Industries reported as expected first-quarter profit and trimmed 2022 revenue estimates due to currency fluctuations.
Teva shares slide 3% premarket as company swings to a loss and revenue falls
07:31am, Tuesday, 03'rd May 2022
Teva Pharmaceutical Industries Ltd. shares TEVA, -2.07% slid 3% in premarket trade Tuesday, after the generics company swung to a loss in the first quarter as revenue fell.
Drug/Biotech Stocks Q1 Earnings Due on May 3: PFE, BIIB & More
07:55pm, Monday, 02'nd May 2022 Zacks Investment Research
Let's look at the five biotech/pharma companies, slated to release quarterly results on May 3.
Drug/Biotech Stocks Q1 Earnings Due on May 3: PFE, BIIB & More
05:18pm, Monday, 02'nd May 2022
Let's look at the five biotech/pharma companies, slated to release quarterly results on May 3.
